Lonza launched Cells on Demand™ Cell Culture and Transfection Services as a new offering for assay-ready cells for cell-based screening. Lonza says the new services cover bulk cell production, transfection services, cell-isolation services, and media production.


Large-scale manufacturing is offered for cell lines, transfected cells, and primary cells including Clonetics® primary cells and Poietics® stem cells. The transfection services include expertise with Amaxa® Nucleofactor® technology for generating stable clones and transiently transfected cells as well as Nucleofection® Protocol Optimization and small-scale protein production.

Previous articleOncodesign to Provide Sanofi-Aventis with Exclusive Cancer Models
Next articleFederal Circuit Holds that Methods of Optimizing Drug Efficacy Are Patentable